Ser88
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser88  -  EPB41L3 (human)

Site Information
QLEDDKLsQKssssK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456369
Available spectra:  1 CST
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 )
Disease tissue studied:
breast cancer ( 9 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 8 ) , acute megakaryoblastic leukemia (M7) ( 8 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 8 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 8 ) , acute myeloblastic leukemia, without maturation (M1) ( 8 ) , lung cancer ( 5 , 6 , 9 ) , non-small cell lung cancer ( 5 , 9 ) , non-small cell lung adenocarcinoma ( 5 , 6 ) , non-small cell large cell lung carcinoma ( 5 ) , B cell lymphoma ( 8 ) , non-Hodgkin's lymphoma ( 8 ) , ovarian cancer ( 4 ) , multiple myeloma ( 8 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 17 ) , 293E (epithelial) ( 13 ) , A498 (renal) ( 18 ) , AML-193 (monocyte) ( 8 ) , breast ( 1 ) , BT-20 (breast cell) ( 9 ) , BT-549 (breast cell) ( 9 ) , Calu 6 (pulmonary) ( 9 ) , CMK (megakaryoblast) ( 8 ) , CTS (myeloid) ( 8 ) , DOHH2 ('B lymphocyte, precursor') ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 10 ) , GM00200 (fibroblast) ( 24 , 25 ) , GM18366 (fibroblast) ( 26 ) , H2009 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H2887 (pulmonary) ( 9 ) , H322 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC1359 (pulmonary) ( 9 ) , HCC1937 (breast cell) ( 9 ) , HCC2279 (pulmonary) ( 9 ) , HCC366 (pulmonary) ( 9 ) , HCC4006 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 9 ) , HEL (erythroid) ( 8 ) , HeLa (cervical) ( 14 , 15 , 19 , 20 , 21 , 22 , 23 ) , HOP62 (pulmonary) ( 9 ) , HUES-9 ('stem, embryonic') ( 16 ) , Kasumi-1 (myeloid) ( 8 ) , KG-1 (myeloid) ( 8 ) , LCLC-103H (pulmonary) ( 9 ) , LOU-NH91 (squamous) ( 9 ) , lung ( 5 , 6 ) , MCF-7 (breast cell) ( 9 ) , MDA-MB-231 (breast cell) ( 9 ) , MDA-MB-468 (breast cell) ( 9 ) , MV4-11 (macrophage) ( 8 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H157 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H2172 (pulmonary) ( 9 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 5 , 9 ) , NCI-H520 (squamous) ( 9 ) , OPM-2 (plasma cell) ( 8 ) , ovary ( 4 ) , P31/FUJ (erythroid) ( 8 ) , PC9 (pulmonary) ( 9 ) , RL ('B lymphocyte, precursor') ( 8 ) , RPMI-8226 (plasma cell) ( 8 ) , SU-DHL-6 (B lymphocyte) ( 8 ) , U266 (plasma cell) ( 8 ) , WM239A (epidermal) ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

7

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

8

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

9

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

10

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

11

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

12

Rikova K (2012) CST Curation Set: 13737; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

13

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

14

Zhou J (2011) CST Curation Set: 11709; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

15

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

16

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

17

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

18

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

19

Zhou J (2009) CST Curation Set: 6246; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

20

Zhou J (2009) CST Curation Set: 6247; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

21

Zhou J (2009) CST Curation Set: 6241; Year: 2009; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

22

Zhou J (2009) CST Curation Set: 6240; Year: 2009; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

23

Zhou J (2008) CST Curation Set: 4706; Year: 2008; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

24

Stokes M (2006) CST Curation Set: 1772; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

25

Stokes M (2006) CST Curation Set: 1773; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

26

Stokes M (2006) CST Curation Set: 1775; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info